A. Ravindran
Centre for Addictions and Mental Health, Toronto, Ont.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name A. Ravindran as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:17 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT00958633 · Mood Stabilizer (MS)+ Antidepressant vs MS + Placebo in Maintenance of Bipolar Disorder.University of British Columbia · terminated · Bipolar I Disorder · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 9 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:17 UTC. The ranking covers the 200 most relevant of 49 PubMed records, and a shared surname and initials can bring in a namesake. All 49 on PubMed
- Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).Int J Neuropsychopharmacol · 2019352 citationsRCR 21.1
- Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.J Clin Psychiatry · 1999212 citationsRCR 8.0
- Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.Br J Psychiatry · 2003197 citationsRCR 6.9
- Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.J Clin Psychiatry · 2008100 citationsRCR 3.2
- Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors.J Psychiatry Neurosci · 1995100 citationsRCR 3.6
- A randomized double-blind sham-controlled comparison of unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant major depression.World J Biol Psychiatry · 201293 citationsRCR 3.7
- Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments.Am J Psychiatry · 199985 citationsRCR 3.0
- Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.J Clin Psychiatry · 201979 citationsRCR 4.5
- Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.Biol Psychiatry · 199779 citationsRCR 3.1
- Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.J Clin Psychopharmacol · 200376 citationsRCR 2.6